[Chance of hepatic fibrosis treatment in chronic hepatitis C].
Treatment of liver fibrosis in chronic hepatitis C should affect at least one among elements of fibrosis pathogenesis. At the present time the only accessible therapeutic method is clearance of HCV infection using combined treatment with pegylated interferon alpha and ribavirin. Other therapeutic opportunities, that can be applied shortly include: reduction of hepatocytes apoptosis by caspase inhibitors, decrease of inflammation intensity using interleukin-10, and inhibition of hepatic stellate cells transformation into myofibroblasts with interferon-gamma. Efficiency of purified phospholipids acting as metalloproteinases inducers or antagonists of profibrogenic cytokines need further evaluation.
Flisiak
Robert
R
Klinika Obserwacyjno-Zakaźna Akademii Medycznej w Białymstoku.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D061945:Caspase Inhibitors; D016923:Cell Death / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D016753:Interleukin-10 / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000821:virology*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012254:Ribavirin / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D061945:Caspase Inhibitors; D016898:Interferon-alpha; D016753:Interleukin-10; D011092:Polyethylene Glycols; D012254:Ribavirin; D007371:Interferon-gamma